Tarsus Pharmaceuticals, Inc. 8-K

What Happened
Tarsus Pharmaceuticals, Inc. announced on its Form 8-K (filed July 8, 2026) that on July 6, 2026 it completed the acquisition of iRenix Medical, Inc. under an Agreement and Plan of Merger. iRenix now operates as a wholly owned subsidiary of Tarsus after Merger Sub merged with and into iRenix. The upfront purchase price consisted of $37,500,000 in cash (subject to customary post‑closing adjustments) and issuance of 607,093 shares of Tarsus common stock.

Key Details

• Transaction closed July 6, 2026; 8-K and related press release dated July 8, 2026.
• Up-front consideration: $37,500,000 cash plus 607,093 shares of Tarsus common stock.
• Additional contingent consideration: up to $490,000,000 in milestone payments tied to regulatory/commercial milestones, plus low‑to‑mid single‑digit revenue‑sharing on future net sales of certain products.
• An escrow was established to secure indemnification obligations and any purchase price adjustments; Fortis Advisors served as the securityholders’ representative.

Why It Matters
This is a strategic acquisition that adds iRenix and its assets to Tarsus’s portfolio with a modest upfront cash/stock outlay and substantial upside tied to future milestones and sales. For investors, the deal affects Tarsus’s share count (issuance of ~607k shares), near‑term cash use ($37.5M subject to adjustments), and introduces contingent liabilities/benefits (up to $490M in milestones and ongoing revenue sharing). The escrow and customary deal protections aim to limit post‑closing risk from the sellers.